150 related articles for article (PubMed ID: 16757431)
1. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
Naito K; Kobayashi M; Sahara N; Shigeno K; Nakamura S; Shinjo K; Tobita T; Takeshita A; Ohno R; Ohnishi K
Int J Hematol; 2006 May; 83(4):318-23. PubMed ID: 16757431
[TBL] [Abstract][Full Text] [Related]
2. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
[TBL] [Abstract][Full Text] [Related]
3. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
[No Abstract] [Full Text] [Related]
4. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Shigeno K; Naito K; Sahara N; Kobayashi M; Nakamura S; Fujisawa S; Shinjo K; Takeshita A; Ohno R; Ohnishi K
Int J Hematol; 2005 Oct; 82(3):224-9. PubMed ID: 16207595
[TBL] [Abstract][Full Text] [Related]
6. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
7. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
[TBL] [Abstract][Full Text] [Related]
8. QT prolongation: a case of arsenical pericardial and pleural effusion.
Vizzardi E; Zanini G; Antonioli E; D'Aloia A; Raddino R; Cas LD
Cardiovasc Toxicol; 2008 Mar; 8(1):41-4. PubMed ID: 18084726
[TBL] [Abstract][Full Text] [Related]
9. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
10. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Barbey JT; Soignet S
Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
[No Abstract] [Full Text] [Related]
11. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
12. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas RA; Seftel MD; Ducas J; Seifer C
J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
[TBL] [Abstract][Full Text] [Related]
13. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
[TBL] [Abstract][Full Text] [Related]
14. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
[No Abstract] [Full Text] [Related]
15. Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia.
Kishi S; Yoshida A; Yamauchi T; Tsutani H; Lee JD; Nakamura T; Naiki H; Ueda T
Int J Hematol; 2000 Feb; 71(2):172-9. PubMed ID: 10745628
[TBL] [Abstract][Full Text] [Related]
16. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Westervelt P; Brown RA; Adkins DR; Khoury H; Curtin P; Hurd D; Luger SM; Ma MK; Ley TJ; DiPersio JF
Blood; 2001 Jul; 98(2):266-71. PubMed ID: 11435292
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide and olanzapine co-administration: case analysis.
Kaufman KR; Chhabra S; Levitt M; Sood R
J Oncol Pharm Pract; 2011 Sep; 17(3):260-4. PubMed ID: 20015926
[TBL] [Abstract][Full Text] [Related]
18. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
[TBL] [Abstract][Full Text] [Related]
19. Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
Kajiguchi T; Yamamoto K; Sawa M; Emi N; Naoe T
Leukemia; 2005 Apr; 19(4):674-6. PubMed ID: 15690072
[No Abstract] [Full Text] [Related]
20. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
